References
- Zhang F, Dou Z, Yu L, et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis. 2008;47:825–8.
- Li N, Wang Z, Sun D, et al. HIV among plasma donors and other high-risk groups in Henan, China. J Acquir Immune Defic Syndr. 2010;53:S41–47.
- Lima VD, Reuter A, Harrigan PR, et al. Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes. AIDS. 2015;29:1871–1882.
- Liu J, Fan PY, Xue XJ, et al. Characteristics of long-term nonprogressors and viremia controllers infected with HIV-1 via contaminated blood donations or transfusions conducted 20 years earlier. Biomed Environ Sci. 2017;30:907–912.
- World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva: World Health Organization; 2016.
- Chen L, Pan X, Ma Q, et al. HIV cause-specific deaths, mortality, risk factors, and the combined influence of HAART and late diagnosis in Zhejiang, China, 2006-2013. Sci Rep. 2017;7:42366.
- Lacny S, Wilson T, Clement F, et al. Kaplan-Meier survival analysis overestimates the risk of revision arthroplasty: a meta-analysis. Clin Orthop Relat Res. 2015;473:3431–3442.
- Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant. 2007;40:381–387.
- Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133:601–609.
- Li M, Tang W, Bu K, et al. Mortality among people living with HIV and AIDS in China: implications for enhancing linkage. Sci Rep. 2016;6:28005.
- Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
- Alba AC, Agoritsas T, Walsh M, et al. Discrimination and calibration of clinical prediction models: users’ guides to the medical literature. JAMA. 2017;318:1377–1384.
- Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
- Migueles SA, Connors M. Success and failure of the cellular immune response against HIV-1. Nat Immunol. 2015;16:563–570.
- Ghate M, Deshpande S, Tripathy S, et al. Incidence of common opportunistic infections in HIV-infected individuals in Pune, India: analysis by stages of immunosuppression represented by CD4 counts. Int J Infect Dis. 2009;13:e1–8.
- Mao Y, Wu Z, Poundstone K, et al. Development of a unified web-based national HIV/AIDS information system in China. Int J Epidemiol. 2010;39:ii79–89.
- Sterne JAC, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352–1363.
- Jose S, Quinn K, Hill T, et al. Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy. AIDS. 2014;28:1333–1339.
- Lundgren JD, Babiker AG, Gordin FM, et al. When to start antiretroviral therapy: the need for an evidence base during early HIV infection. BMC Med. 2013;11. DOI:https://doi.org/10.1186/1741-7015-11-148
- Katz IT, Essien T, Marinda ET, et al. Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. AIDS. 2011;25:2177–2181.
- Nachega JB, Uthman OA, Del Rio C, et al. Addressing the Achilles’ heel in the HIV care continuum for the success of a test-and-treat strategy to achieve an AIDS-free generation. Clin Infect Dis. 2014;59:S21–27.
- Gallant JE, Mehta SH, Sugarman J. Universal antiretroviral therapy for HIV infection: should us treatment guidelines be applied to resource-limited settings? Clin Infect Dis. 2013;57:884–887.
- Ford N, Meintjes G, Pozniak A, et al. The future role of CD4 cell count for monitoring antiretroviral therapy. Lancet Infect Dis. 2015;15:241–247.
- Zhao Y, Wu Z, McGoogan JM, et al. Immediate antiretroviral therapy decreases mortality among patients with high CD4 counts in china: a nationwide, retrospective cohort study. Clin Infect Dis. 2018;66:727–734.
- Damtew B, Mengistie B, Alemayehu T. Survival and determinants of mortality in adult HIV/Aids patients initiating antiretroviral therapy in Somali Region, Eastern Ethiopia. Pan Afr Med J. 2015;22:138.
- Dou Z, Chen RY, Wang Z, et al. HIV-infected former plasma donors in rural Central China: from infection to survival outcomes, 1985-2008. PLoS One. 2010;5:e13737.
- Yang RR, Gui X, Benoit JL, et al. The comparison of human immunodeficiency virus type 1 transmission between couples through blood or sex in central China. Jpn J Infect Dis. 2010;63:283–285.
- Greig J, Casas EC, O’Brien DP, et al. Association between older age and adverse outcomes on antiretroviral therapy: a cohort analysis of programme data from nine countries. AIDS. 2012;26:S31–37.
- Akbari M, Fararouei M, Haghdoost AA, et al. Survival and associated factors among people living with HIV/AIDS: a 30-year national survey in Iran. J Res Med Sci. 2019;24:5.
- Keaei M, Kuhlmann J, Conde R, et al. Health-related quality of life of patients with HIV/AIDS in Bogotá, Colombia. Value Health Reg Issues. 2016;11:68–72.
- Jiang T, Zhou X, Wang H, et al. Psychosocial factors associated with quality of life in young men who have sex with men living with HIV/AIDS in Zhejiang, China. Int J Environ Res Public Health. 2019;16. DOI:https://doi.org/10.3390/ijerph16152667
- Mgwaba T, Maharaj P. Unpacking the practice of ukujola in contemporary South Africa: understanding informal/casual sexual relations of young African adults in the context of HIV and AIDS. Afr J AIDS Res. 2018;17:341–351.
- Zhang Z, Cortese G, Combescure C, et al. Overview of model validation for survival regression model with competing risks using melanoma study data. Ann Transl Med. 2018;6:325.
- Li CX, Li YY, He LP, et al. The predictive role of CD4(+) cell count and CD4/CD8 ratio in immune reconstitution outcome among HIV/AIDS patients receiving antiretroviral therapy: an eight-year observation in China. BMC Immunol. 2019;20:31.